Baihui Pharmaceutical Group

Blog

28

2019-05

Outstanding Partner

Outstanding Partner

2019-05-28

Outstanding Partner

28

2019-05

Best Planning Proposal Award

Best Planning Proposal Award

2019-05-28

Best Planning Proposal Award

28

2019-05

Best Partner

Best Partner

2019-05-28

Best Partner

28

2019-05

Best Potential Award

Best Potential Award

2019-05-28

Best Potential Award

28

2019-05

Imported drugs are getting cheaper, while locally developed innovative medicines find themselves in an awkward situation.

Recently, a report titled "Why Has This Major Innovative Drug—Which Could Significantly Lower Prices of Imported Medicines—Still Not Been Included in National Reimbursement Programs Nine Years After Its Launch?" has sparked strong reactions within the industry. With reforms in new drug approval processes and the ongoing advancement of generic drug consistency evaluations, Chinese pharmaceutical companies are growing increasingly enthusiastic about developing innovative medicines. However, despite being domestically developed and innovative, the market performance of these drugs remains mixed—some thrive, while others struggle. For instance, China's first Class 1.1 fluoroquinolone antibacterial agent, which boasts independent intellectual property rights, has yet to be added to the national medical insurance catalog or the essential drug lists of public healthcare institutions in most regions, even after nine years on the market. Meanwhile, another Class 1 new drug developed entirely with domestic expertise…

2019-05-28

Imported drugs are getting cheaper, while locally developed innovative medicines find themselves in an awkward situation.

28

2019-05

The scope of medical insurance drug reimbursement is expanding—Which pharmaceutical companies will benefit?

On May 13, the National Healthcare Security Administration, jointly with the Ministry of Finance, issued the "Notice on Doing a Good Job in Basic Medical Insurance for Urban and Rural Residents in 2019," which clearly emphasized the need to establish and improve a unified outpatient expense management and payment mechanism for urban and rural residents' medical insurance, with a particular focus on safeguarding against the heavy financial burdens posed by common and chronic diseases. Specifically, medications prescribed for outpatient treatment of conditions such as hypertension and diabetes will now be included in the scope of medical insurance reimbursement.

2019-05-28

< 1...23242526 >

Sorry，当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry，The current column has no content!

You can view other columns or return Home